Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-07-23
DOI
10.1038/s41375-022-01657-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
- (2021) Jeroen Janssen et al. Cancers
- Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
- (2021) Bob Löwenberg et al. Blood Advances
- Updated overall survival of eltanexor for the treatment of patients with hypomethylating agent refractory myelodysplastic syndrome.
- (2021) Sangmin Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- A 2:1 randomized, open-label, phase II study of selinexor vs. physician’s choice in older patients with relapsed or refractory acute myeloid leukemia
- (2021) Kendra Sweet et al. LEUKEMIA & LYMPHOMA
- Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy
- (2020) Chong Chyn Chua et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
- (2020) Courtney D. DiNardo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
- (2020) Nagesh Kalakonda et al. Lancet Haematology
- Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
- (2019) Bhavana Bhatnagar et al. LEUKEMIA & LYMPHOMA
- Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
- (2019) Kendra Sweet et al. CLINICAL CANCER RESEARCH
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
- (2018) Jeffrey E. Lancet et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1
- (2018) Daniel A. Luedtke et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia
- (2018) Lauren Veltri et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II to the Nucleus
- (2016) P. Ranganathan et al. CLINICAL CANCER RESEARCH
- Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
- (2015) J Etchin et al. LEUKEMIA
- Prognostic Relevance of Treatment Response Measured by Flow Cytometric Residual Disease Detection in Older Patients With Acute Myeloid Leukemia
- (2013) Sylvie D. Freeman et al. JOURNAL OF CLINICAL ONCOLOGY
- High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
- (2013) Monique Terwijn et al. JOURNAL OF CLINICAL ONCOLOGY
- Older Patients With Acute Myeloid Leukemia Benefit From Intensive Chemotherapy: An Update From the Swedish Acute Leukemia Registry
- (2011) Gunnar Juliusson Clinical Lymphoma Myeloma & Leukemia
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started